- Datum23.10.2024
- Uhrzeit15:00 - 15:30 Uhr
- Veranstalterstock3
Chugai Pharmaceutical Co. Ltd. Chart
Du willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnenChugai Pharmaceutical Co. Ltd. Realtime-Kurs
Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
---|---|---|---|---|---|---|
L&S | VK | |||||
Tradegate | VK | |||||
Stuttgart | VK |
Passende Produkte
WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
---|
Keine Ergebnisse gefunden
Wertentwicklung (L&S)
-1,81 %
Intraday
-6,82 %
1 Woche
-1,02 %
1 Monat
24,52 %
Seit Jahresbeginn
48,37 %
1 Jahr
41,69 %
3 Jahre
87,34 %
5 Jahre
Wikifolio
Passender Service zu Chugai Pharmaceutical Co. Ltd.
Webinar zu Chugai Pharmaceutical Co. Ltd.
Kursinformationen (L&S)
- Tagestief / Hoch (€)-
- 52W-Tief / Hoch (€)27,000-46,000
- Jahrestief / Hoch (€)27,010-46,000
- Schlusskurs (Vortag)
- Eröffnungskurs
Wichtigste Eigenschaften
Dividenden von Chugai Pharmaceutical Co. Ltd.
Termine von Chugai Pharmaceutical Co. Ltd.
- Okt25Chugai Pharmaceutical Co. Ltd.Q3 2024 Earnings Release
- Jan30Chugai Pharmaceutical Co. Ltd.Q4 2024 Earnings Release
- Apr23Chugai Pharmaceutical Co. Ltd.Q1 2025 Earnings Release
Beschreibung
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and covid-19 patients.